Cytospector’s assay for schizophrenia evaluates the effect of selected compounds or genes on disease-associated pathways. This assay can be used to identify novel therapeutics or targets for schizophrenia.
MicroRNA-137 (MIR137) has been implicated in the development of schizophrenia by GWAS and functional studies. MIR137 regulates several pathways that are involved in the etiology of this disorder. By genetically targeting MIR137, we induce a synaptic phenotype that mimics schizophrenia-associated pathology in humans. Our schizophrenia assay evaluates the potency of selected experimental manipulations to rescue this synaptic phenotype.